SCHEMBL4473406

SCHEMBL4473406

CCOC(=O)c1nc(O)c(O)c2c1CCN(Cc1ccc(F)c(Cl)c1)C2=O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 1/20 0.38
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
AKR1B1 P15121 1/20 0.35
P2RX7 Q99572 3/20 0.35
KDM4E B2RXH2 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PKM P14618 1/20 0.34
TNIK Q9UKE5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336725 0.91 MEN1 (0.41) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL10233489 0.86 GPR52 (0.40) AKR1B1PIK3CDPIK3CAPIK3CBTNIK
SCHEMBL1336916 0.86 MEN1 (0.42) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL1335730 0.86 AKR1B1 (0.36) AKR1B1PIK3CDPIK3CAPIK3CBTNIK
SCHEMBL6031924 0.85 PIK3CD (0.39) AKR1B1P2RX7PIK3CDPIK3CAPIK3CB
SCHEMBL1337301 0.84 ALDH1A1 (0.38) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL4939209 0.83 ALDH1A1 (0.43) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL1335829 0.83 MEN1 (0.37) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL1336853 0.83 P2RX7 (0.42) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL2728768 0.82 GPR52 (0.44) AKR1B1PIK3CDPIK3CAPIK3CBTNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP disclosed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO disclosed
WO-2005087767-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H ALDH1A1 1500/4885MEN1 4754/4885KMT2A 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.